Home Cart 0 Sign in  
X

[ CAS No. 1126-46-1 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 1126-46-1
Chemical Structure| 1126-46-1
Chemical Structure| 1126-46-1
Structure of 1126-46-1 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 1126-46-1 ]

Related Doc. of [ 1126-46-1 ]

Alternatived Products of [ 1126-46-1 ]
Product Citations

Product Details of [ 1126-46-1 ]

CAS No. :1126-46-1 MDL No. :MFCD00000621
Formula : C8H7ClO2 Boiling Point : -
Linear Structure Formula :- InChI Key :LXNFVVDCCWUUKC-UHFFFAOYSA-N
M.W : 170.59 Pubchem ID :14307
Synonyms :

Calculated chemistry of [ 1126-46-1 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.12
Num. rotatable bonds : 2
Num. H-bond acceptors : 2.0
Num. H-bond donors : 0.0
Molar Refractivity : 42.73
TPSA : 26.3 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.3 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.22
Log Po/w (XLOGP3) : 2.87
Log Po/w (WLOGP) : 2.13
Log Po/w (MLOGP) : 2.52
Log Po/w (SILICOS-IT) : 2.33
Consensus Log Po/w : 2.41

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.98
Solubility : 0.18 mg/ml ; 0.00105 mol/l
Class : Soluble
Log S (Ali) : -3.08
Solubility : 0.141 mg/ml ; 0.000829 mol/l
Class : Soluble
Log S (SILICOS-IT) : -3.08
Solubility : 0.141 mg/ml ; 0.000824 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.15

Safety of [ 1126-46-1 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 1126-46-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1126-46-1 ]
  • Downstream synthetic route of [ 1126-46-1 ]

[ 1126-46-1 ] Synthesis Path-Upstream   1~14

  • 1
  • [ 55-22-1 ]
  • [ 62-53-3 ]
  • [ 3034-31-9 ]
  • [ 1126-46-1 ]
YieldReaction ConditionsOperation in experiment
89%
Stage #1: With 1,1'-carbonyldiimidazole In N,N-dimethyl-formamide at 40℃; for 2.5 h;
Stage #2: for 20 h;
A solution of 1,10-carbonyldiimidazole (130 g,0.81 mol), isonicotinic acid (100 g, 0.81 mol) and DMF (300 mL) was heated at 40 C for 2.5 h before aniline (100 g, 0.81 mol) was added in a single portion. After 20 h, water (1.2 L) was added. The resulting suspension was filtered andthe solids dried under vacuum to afford isonicotinanilide (39) (142.6 g, 89percent).
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2015, vol. 25, # 4, p. 976 - 981
  • 2
  • [ 1126-46-1 ]
  • [ 536-40-3 ]
YieldReaction ConditionsOperation in experiment
93.4% With hydrazine hydrate In ethanol for 5 h; Reflux General procedure: A solution of hydrazine hydrate (20.00 mmol) in 2 mL EtOH was added dropwise to the ester 2 (5.00 mmol). The mixture was refluxed for 5 h and filtered, and the corresponding acid hydrazide 3 was obtained by washing the residue with ice water.
92% With hydrazine hydrate In methanolReflux General procedure: Compound (2) (0.1 mol) was taken in a round-bottom flaskwith methanol (100 mL). Hydrazine hydrate (99percent) (0.15mol, 5.7 mL) was added drop wise with gentle stirring. Thereaction mixture was refluxed for 4–6 h. Excess of methanolwas distilled off under reduced pressure. The precipitatedhydrazide was dried and re-crystallized from methanol(Zamani and Faghihi 2003).
88% With hydrazine hydrate In water at 50 - 60℃; for 0.166667 h; General procedure: Pathway A-Hydrazine hydrate 64percent (v/v) (30.0 mL, 0.33 mol) was heated up to 50-60 °C. The methyl ester previously isolated (0.01 mol) was added and the mixture was refluxed during 10 min. The cooling down was proceeded sequentially in a water bath, followed by ice bath and dry ice - ethanol bath. The solid was filtered and washed with cold water. Different conditions were needed to obtain 4-nitro-3-(trifluoromethyl)benzhydrazide (3d) and 4-nitrobenzhydrazide (3 h). Hydrazine hydrate 64percent (v/v) (30.0 mL, 0.33 mol) was cooled down in ice bath to -3 to 2 °C. The respective methyl ester (0.01 mol) was added and the mixture was stirred during 1 hour. The cooling down was proceeded in dry ice - ethanol bath. The solid was filtered and washed with cold water. Pathway B-each substituted benzoic acid (0.01 mol) was refluxed during 4 h in 20.0 mL (0.50 mol) of anhydrous methanol and 0.5 mL (1.0 mmol) of sulfuric acid. The reaction mixture was cooled down to room temperature. and the hydrazine hydrate 80percent (v/v) (10.0 mL, 0.11 mol) was added. The system was maintained into vigorously stirring for more 30 minutes. In the case of compounds with 4-nitro and 4-nitro-3-trifluoromethyl substituent groups attached in the benzene moiety, after the addition of hydrazine hydrate 80percent (v/v) at room temperature, the reaction mixture was cooled down in ice bath and maintained into stirring during 1 hour. After these periods, the mixture was maintained at cold temperature to give 3.
82.4% With hydrazine hydrate In ethanolReflux General procedure: To a solution of the appropriate methyl benzoate ester (1.0 mmol) in ethanol (30 mL), hydrazine monohydrate (0.15 g, 3.0 mmol) was added. The reaction mixture was heated under reflux overnight. After completion of the reaction, the solvent was evaporated under reduced pressure, and the residue was washed with water (2 x 3 mL), and the obtained solid was filtered and dried to give benzohydrazide derivatives 3a-c.

Reference: [1] European Journal of Medicinal Chemistry, 1985, vol. 20, # 3, p. 257 - 266
[2] European Journal of Medicinal Chemistry, 2014, vol. 74, p. 73 - 84
[3] Medicinal Chemistry Research, 2017, vol. 26, # 10, p. 2260 - 2271
[4] Arzneimittel-Forschung/Drug Research, 2001, vol. 51, # 7, p. 569 - 573
[5] Letters in Drug Design and Discovery, 2012, vol. 9, # 3, p. 276 - 281
[6] Bioorganic and Medicinal Chemistry, 2011, vol. 19, # 16, p. 5031 - 5038
[7] Journal of Medicinal Chemistry, 2016, vol. 59, # 6, p. 2362 - 2380
[8] New Journal of Chemistry, 2016, vol. 40, # 10, p. 8846 - 8854
[9] European Journal of Medicinal Chemistry, 2015, vol. 90, p. 45 - 52
[10] Molecules, 2010, vol. 15, # 12, p. 9046 - 9056
[11] Bollettino Chimico Farmaceutico, 1997, vol. 136, # 3, p. 244 - 249
[12] Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1980, vol. 19, # 4, p. 260 - 262
[13] Bioorganic and medicinal chemistry, 2002, vol. 10, # 3, p. 557 - 560
[14] Bioorganic and Medicinal Chemistry, 2007, vol. 15, # 12, p. 4229 - 4236
[15] Journal of Heterocyclic Chemistry, 2007, vol. 44, # 5, p. 1023 - 1027
[16] Bioorganic and Medicinal Chemistry, 2008, vol. 16, # 14, p. 6724 - 6731
[17] Bioorganic and Medicinal Chemistry, 2009, vol. 17, # 8, p. 3028 - 3036
[18] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2009, vol. 48, # 3, p. 460 - 466
[19] Journal of the American Chemical Society, 2010, vol. 132, # 20, p. 6900 - 6901
[20] Zeitschrift fur Naturforschung - Section B Journal of Chemical Sciences, 2010, vol. 65, # 2, p. 178 - 184
[21] Organic Letters, 2010, vol. 12, # 15, p. 3567 - 3569
[22] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2010, vol. 49, # 4, p. 475 - 481
[23] European Journal of Medicinal Chemistry, 2010, vol. 45, # 11, p. 5200 - 5207
[24] Monatshefte fur Chemie, 2010, vol. 141, # 4, p. 479 - 484
[25] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 16, p. 4919 - 4923
[26] Bioorganic and Medicinal Chemistry, 2011, vol. 19, # 21, p. 6293 - 6301
[27] Journal of Molecular Structure, 2011, vol. 1003, # 1-3, p. 52 - 61
[28] Magnetic Resonance in Chemistry, 2011, vol. 49, # 10, p. 648 - 654
[29] Journal of Molecular Structure, 2012, vol. 1011, p. 121 - 127
[30] Arzneimittel-Forschung/Drug Research, 2011, vol. 61, # 8, p. 452 - 457
[31] Angewandte Chemie - International Edition, 2012, vol. 51, # 19, p. 4666 - 4670
[32] Molecules, 2012, vol. 17, # 5, p. 5095 - 5107
[33] Journal of Medicinal Chemistry, 2012, vol. 55, # 17, p. 7525 - 7545
[34] Phosphorus, Sulfur and Silicon and the Related Elements, 2012, vol. 187, # 11, p. 1401 - 1408
[35] Bulletin of the Korean Chemical Society, 2012, vol. 33, # 12, p. 3943 - 3949
[36] Bulletin of the Korean Chemical Society, 2012, vol. 33, # 12, p. 4180 - 4184
[37] Medicinal Chemistry, 2012, vol. 8, # 6, p. 1190 - 1197,8
[38] Medicinal Chemistry, 2012, vol. 8, # 6, p. 1190 - 1197
[39] Zeitschrift fur Naturforschung - Section B Journal of Chemical Sciences, 2015, vol. 70, # 8, p. 609 - 616
[40] Journal of Heterocyclic Chemistry, 2018, vol. 55, # 4, p. 863 - 870
[41] Australian Journal of Chemistry, 2012, vol. 65, # 10, p. 1413 - 1419,7
[42] Australian Journal of Chemistry, 2012, vol. 65, # 10, p. 1413 - 1419
[43] Chemical Communications (Cambridge, United Kingdom), 2012, vol. 48, # 92, p. 11307 - 11309,3
[44] Medicinal Chemistry Research, 2013, vol. 22, # 3, p. 1305 - 1312
[45] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 17, p. 5395 - 5406
[46] Medicinal Chemistry Research, 2013, vol. 22, # 10, p. 4980 - 4991
[47] Chemical Biology and Drug Design, 2013, vol. 82, # 5, p. 546 - 556
[48] Comptes Rendus Chimie, 2015, vol. 18, # 12, p. 1320 - 1327
[49] Phosphorus, Sulfur and Silicon and the Related Elements, 2016, vol. 191, # 6, p. 904 - 907
[50] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 1, p. 192 - 194
[51] Polyhedron, 2014, vol. 68, p. 164 - 171
[52] European Journal of Medicinal Chemistry, 2014, vol. 80, p. 167 - 174
[53] Medicinal Chemistry Research, 2014, vol. 23, # 4, p. 1661 - 1671
[54] Synthetic Communications, 2014, vol. 44, # 18, p. 2724 - 2737
[55] European Journal of Medicinal Chemistry, 2014, vol. 87, p. 175 - 185
[56] New Journal of Chemistry, 2015, vol. 39, # 1, p. 453 - 460
[57] Bioorganic and Medicinal Chemistry Letters, 2015, vol. 25, # 3, p. 481 - 484
[58] Chemical Communications, 2015, vol. 51, # 76, p. 14365 - 14368
[59] Patent: WO2016/108249, 2016, A1, . Location in patent: Paragraph 063
[60] Journal of Heterocyclic Chemistry, 2016, vol. 53, # 5, p. 1651 - 1654
[61] Bioorganic Chemistry, 2016, vol. 69, p. 48 - 63
[62] Letters in Drug Design and Discovery, 2016, vol. 13, # 9, p. 968 - 981
[63] Journal of the Chemical Society of Pakistan, 2016, vol. 38, # 5, p. 864 - 881
[64] Chemical Biology and Drug Design, 2017, vol. 89, # 1, p. 47 - 60
[65] Arkivoc, 2016, vol. 2017, # 2, p. 87 - 106
[66] Oriental Journal of Chemistry, 2017, vol. 33, # 1, p. 335 - 345
[67] Chemical Biology and Drug Design, 2017, vol. 90, # 2, p. 200 - 209
[68] Patent: CN106866708, 2017, A, . Location in patent: Paragraph 0059; 0066; 0073
[69] Arkivoc, 2017, vol. 2017, # 5, p. 293 - 300
[70] Bulletin of the Chemical Society of Ethiopia, 2017, vol. 31, # 3, p. 481 - 489
[71] Pharmaceutical Chemistry Journal, 2018, vol. 51, # 10, p. 907 - 917
[72] Bioorganic and Medicinal Chemistry, 2018, vol. 26, # 8, p. 1971 - 1985
[73] Letters in Drug Design and Discovery, 2018, vol. 15, # 4, p. 363 - 374
[74] Bioorganic and Medicinal Chemistry Letters, 2018,
  • 3
  • [ 1126-46-1 ]
  • [ 14719-83-6 ]
Reference: [1] Patent: US2680730, 1950, ,
[2] Patent: US2680730, 1950, ,
  • 4
  • [ 1126-46-1 ]
  • [ 7697-37-2 ]
  • [ 14719-83-6 ]
Reference: [1] Recueil des Travaux Chimiques des Pays-Bas, 1900, vol. 19, p. 55
  • 5
  • [ 67-56-1 ]
  • [ 3395-81-1 ]
  • [ 1126-46-1 ]
  • [ 22911-21-3 ]
Reference: [1] Tetrahedron, 1986, vol. 42, # 2, p. 553 - 560
[2] Tetrahedron, 1986, vol. 42, # 2, p. 553 - 560
  • 6
  • [ 1126-46-1 ]
  • [ 18469-52-8 ]
Reference: [1] Organic Letters, 2012, vol. 14, # 11, p. 2818 - 2821
  • 7
  • [ 1126-46-1 ]
  • [ 201230-82-2 ]
  • [ 62-53-3 ]
  • [ 3814-10-6 ]
Reference: [1] Journal of Organic Chemistry, 1996, vol. 61, # 21, p. 7482 - 7485
  • 8
  • [ 1126-46-1 ]
  • [ 4068-78-4 ]
  • [ 22717-55-1 ]
  • [ 873-76-7 ]
Reference: [1] Organic and Biomolecular Chemistry, 2008, vol. 6, # 7, p. 1251 - 1259
  • 9
  • [ 1126-46-1 ]
  • [ 57381-62-1 ]
Reference: [1] Angewandte Chemie - International Edition, 2013, vol. 52, # 16, p. 4440 - 4444[2] Angew. Chem., 2013, vol. 125, # 16, p. 4536 - 4540,5
  • 10
  • [ 1126-46-1 ]
  • [ 160598-47-0 ]
Reference: [1] Journal of Organic Chemistry, 2013, vol. 78, # 15, p. 7436 - 7444
  • 11
  • [ 13675-18-8 ]
  • [ 1126-46-1 ]
  • [ 99768-12-4 ]
Reference: [1] Journal of Organic Chemistry, 2018, vol. 83, # 4, p. 1842 - 1851
  • 12
  • [ 705254-34-8 ]
  • [ 93-58-3 ]
  • [ 1126-46-1 ]
  • [ 35112-28-8 ]
  • [ 99768-12-4 ]
Reference: [1] Journal of Organic Chemistry, 2011, vol. 76, # 17, p. 7195 - 7203
  • 13
  • [ 1126-46-1 ]
  • [ 329218-12-4 ]
Reference: [1] Journal of Medicinal Chemistry, 1999, vol. 42, # 20, p. 4088 - 4098
  • 14
  • [ 1126-46-1 ]
  • [ 107947-17-1 ]
Reference: [1] Journal of Medicinal Chemistry, 1999, vol. 42, # 20, p. 4088 - 4098
Recommend Products
Same Skeleton Products

Technical Information

• Acid-Catalyzed α -Halogenation of Ketones • Acyl Group Substitution • Addition of a Hydrogen Halide to an Internal Alkyne • Alcohols Convert Acyl Chlorides into Esters • Alcohols from Haloalkanes by Acetate Substitution-Hydrolysis • Alcoholysis of Anhydrides • Alkyl Halide Occurrence • Alkylation of an Alkynyl Anion • Amines Convert Esters into Amides • An Alkane are Prepared from an Haloalkane • Benzylic Oxidation • Birch Reduction • Birch Reduction of Benzene • Blanc Chloromethylation • Bouveault-Blanc Reduction • Catalytic Hydrogenation • Chloroalkane Synthesis with SOCI2 • Claisen Condensations Produce β-Dicarbonyl Compounds • Claisen Condensations Produce β-Dicarbonyl Compounds • Complete Benzylic Oxidations of Alkyl Chains • Complete Benzylic Oxidations of Alkyl Chains • Complex Metal Hydride Reductions • Conversion of Amino with Nitro • Convert Esters into Aldehydes Using a Milder Reducing Agent • Convert Haloalkanes into Alcohols by SN2 • Decarboxylation of 3-Ketoacids Yields Ketones • Deprotection of Cbz-Amino Acids • Deprotonation of Methylbenzene • Directing Electron-Donating Effects of Alkyl • Electrophilic Chloromethylation of Polystyrene • Ester Cleavage • Ester Hydrolysis • Friedel-Crafts Alkylation of Benzene with Acyl Chlorides • Friedel-Crafts Alkylation of Benzene with Carboxylic Anhydrides • Friedel-Crafts Alkylation of Benzene with Haloalkanes • Friedel-Crafts Alkylation Using Alkenes • Friedel-Crafts Alkylations of Benzene Using Alkenes • Friedel-Crafts Alkylations Using Alcohols • Friedel-Crafts Reaction • General Reactivity • Grignard Reaction • Grignard Reagents Transform Esters into Alcohols • Groups that Withdraw Electrons Inductively Are Deactivating and Meta Directing • Halogenation of Alkenes • Halogenation of Benzene • Hantzsch Pyridine Synthesis • Hiyama Cross-Coupling Reaction • Hydrogenation to Cyclohexane • Hydrogenolysis of Benzyl Ether • Ketones Undergo Mixed Claisen Reactions to Form β-Dicarbonyl Compounds • Kinetics of Alkyl Halides • Kumada Cross-Coupling Reaction • Methylation of Ammonia • Nitration of Benzene • Nucleophilic Aromatic Substitution • Nucleophilic Aromatic Substitution with Amine • Oxidation of Alkyl-substituted Benzenes Gives Aromatic Ketones • Preparation of Alkylbenzene • Reactions of Alkyl Halides with Reducing Metals • Reactions of Amines • Reactions of Benzene and Substituted Benzenes • Reactions with Organometallic Reagents • Reduction of an Ester to an Alcohol • Reduction of an Ester to an Aldehyde • Reductive Removal of a Diazonium Group • Reverse Sulfonation——Hydrolysis • Specialized Acylation Reagents-Carbodiimides and Related Reagents • Stille Coupling • Substitution and Elimination Reactions of Alkyl Halides • Sulfonation of Benzene • Suzuki Coupling • The Acylium Ion Attack Benzene to Form Phenyl Ketones • The Claisen Rearrangement • The Cycloaddition of Dienes to Alkenes Gives Cyclohexenes • The Nitro Group Conver to the Amino Function • Transesterification • Vilsmeier-Haack Reaction
Historical Records

Related Functional Groups of
[ 1126-46-1 ]

Aryls

Chemical Structure| 2905-65-9

[ 2905-65-9 ]

Methyl 3-chlorobenzoate

Similarity: 0.98

Chemical Structure| 20330-90-9

[ 20330-90-9 ]

Dimethyl 5-chloroisophthalate

Similarity: 0.98

Chemical Structure| 7335-27-5

[ 7335-27-5 ]

Ethyl 4-chlorobenzoate

Similarity: 0.96

Chemical Structure| 55737-77-4

[ 55737-77-4 ]

3-Chloro-4-(methoxycarbonyl)benzoic acid

Similarity: 0.94

Chemical Structure| 1128-76-3

[ 1128-76-3 ]

Ethyl 3-chlorobenzoate

Similarity: 0.94

Chlorides

Chemical Structure| 2905-65-9

[ 2905-65-9 ]

Methyl 3-chlorobenzoate

Similarity: 0.98

Chemical Structure| 20330-90-9

[ 20330-90-9 ]

Dimethyl 5-chloroisophthalate

Similarity: 0.98

Chemical Structure| 7335-27-5

[ 7335-27-5 ]

Ethyl 4-chlorobenzoate

Similarity: 0.96

Chemical Structure| 55737-77-4

[ 55737-77-4 ]

3-Chloro-4-(methoxycarbonyl)benzoic acid

Similarity: 0.94

Chemical Structure| 1128-76-3

[ 1128-76-3 ]

Ethyl 3-chlorobenzoate

Similarity: 0.94

Esters

Chemical Structure| 2905-65-9

[ 2905-65-9 ]

Methyl 3-chlorobenzoate

Similarity: 0.98

Chemical Structure| 20330-90-9

[ 20330-90-9 ]

Dimethyl 5-chloroisophthalate

Similarity: 0.98

Chemical Structure| 7335-27-5

[ 7335-27-5 ]

Ethyl 4-chlorobenzoate

Similarity: 0.96

Chemical Structure| 55737-77-4

[ 55737-77-4 ]

3-Chloro-4-(methoxycarbonyl)benzoic acid

Similarity: 0.94

Chemical Structure| 1128-76-3

[ 1128-76-3 ]

Ethyl 3-chlorobenzoate

Similarity: 0.94

; ;